IntegriChain, the leading provider of revenue optimization technology and insights for the pharmaceutical industry, today announced the hiring of Clay Willis. Willis brings IntegriChain more than a decade of experience in pharmaceutical consulting and advisory, predominantly around 340B, contracting, pricing, and market access issues.

“The ever-changing regulatory and pricing landscape poses a tremendous challenge to our customers, and nothing is more troublesome than managing the dynamics of the 340B program,” said Bill Roth, Senior Vice President and Managing Partner, Consulting & Advisory of IntegriChain. “Clay brings decades of industry-proven leadership around these complex issues and will help IntegriChain to deliver even deeper insights as well as decision and operational support.”

“I am excited to join the IntegriChain Advisory team at this pivotal moment,” said Willis. “Our enhanced Consulting and Advisory services, coupled with IntegriChain’s data, technology, and outsourcing capabilities, make IntegriChain ideally suited to address today’s drug commercialization challenges. I look forward to helping IntegriChain’s customers optimize their revenue and mitigate risk in the complex and dynamic world of 340B, IRA, and other government programs.”

About Clay Willis

Clay will be responsible for expansion of IntegriChain’s Government Pricing and Gross to Net Advisory practice, helping companies understand and navigate the dynamic life sciences and healthcare landscape, especially in the areas of 340B Drug Pricing Program (“340B”) and impacts to manufacturers from the Inflation Reduction Act of 2022 (“IRA”). Clay’s specific expertise is based on a detailed understanding of government programs (Medicaid, Medicare, VA/FSS, 340B) strategy, operations, compliance, and overall channel management. He has knowledge in Government Pricing calculation, gross-to-net optimization, forecasting, and 340B strategies, operations, and self-help related solutions. Most recently, Clay was a Director in Berkeley Research Group’s Health Analytics practice where he assisted companies in 340B strategy and operational related matters including helping manufacturers implement 340B Center of Excellence governance and operating models. Previously, Clay held senior-level advisory roles at Deloitte and Huron Consulting where he provided operational, financial, compliance, and strategy related support to small, mid-size, and large pharmaceutical manufacturers. He is a frequent speaker at industry events and is a recognized expert on Government Programs (Medicaid, Medicare, 340B, and VA/FSS) and regulatory dynamics.

About IntegriChain

IntegriChain is the leading provider of revenue optimization technology and insights for the Pharma industry. The company’s unique combination of data management, enterprise applications, consulting, and outsourcing helps manufacturers achieve better financial results by connecting commercial execution to net revenue. IntegriChain is backed by Nordic Capital, a leading sector-specialized private equity investor with a broad portfolio in Healthcare and Technology. IntegriChain is headquartered in Philadelphia, PA, with offices in Ambler, PA, and Pune, India. For more information, visit www.integrichain.com or follow on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250702407272/en/